Anzeige
Mehr »
Montag, 13.10.2025 - Börsentäglich über 12.000 News
Der Lithium Markt ist zurück - und Simon Clarke ist mit dabei!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PVQK | ISIN: CA03783R1073 | Ticker-Symbol:
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
APPILI THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
APPILI THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur APPILI THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.10.Appili Therapeutics Inc: Appili, Vitalex win up to $40M (U.S.) VXV-01 contract1
01.10.Stocks in Play: Appili Therapeutics Inc.1
01.10.Appili receives $3.6 million NIAID contract for fungal vaccine development1
01.10.Appili erhält NIAID-Vertrag über 3,6 Millionen US-Dollar zur Entwicklung eines Pilzimpfstoffs4
01.10.Appili Therapeutics Inc.: Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-0147Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials Submitted up to US$97 million in additional...
► Artikel lesen
APPILI THERAPEUTICS Aktie jetzt für 0€ handeln
24.09.Appili Therapeutics Inc: Appili Therapeutics holders approve AGM resolutions1
23.09.Appili Therapeutics shareholders approve all resolutions at annual meeting2
23.09.Appili Therapeutics Inc.: Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders52HALIFAX, Nova Scotia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for...
► Artikel lesen
15.08.Appili Therapeutics GAAP EPS of -$0.011
14.08.Appili Therapeutics Inc.: Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026121Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million Accepted as a new member of U.S. Medical CBRN Defense Consortium, strengthening...
► Artikel lesen
06.08.Appili Therapeutics Inc: Appili releases tularemia vaccine results1
06.08.Appili Therapeutics Inc.: Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine1
26.06.Appili Therapeutics Inc.: Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results934LIKMEZ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia...
► Artikel lesen
30.05.Stocks in Play: Appili Therapeutics Inc.1
30.05.Appili Therapeutics Inc.: Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.296NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink:...
► Artikel lesen
20.05.Appili Therapeutics Inc: Appili to receive termination fee from Aditxt1
19.05.Aditxt to terminate arrangement agreement with Appili Therapeutics1
19.05.Appili Therapeutics Inc.: Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.269NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink:...
► Artikel lesen
01.05.Appili Therapeutics Inc.: Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia1
28.04.Appili Therapeutics Inc: Appili Therapeutics granted patents in U.S., Mexico1
Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1